GlassScriptPhysician profile
Jeffrey M Schulman
NPI 1033148614
$918.65
in general payments reported to CMS, 2019-2025
14 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.96 · 2022: $33.80 · 2023: $377 · 2024: $227 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $116.18 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $100.15 | 2021-2025 | |
| Evofem Biosciences, INC. | $98.50 | 2024-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $91.86 | 2023-2025 | Nexplanon, Nuvaring |
| Myriad Women'S Health, INC. | $89.01 | 2023 | Myrisk |
| Abbvie INC. | $82.54 | 2021-2024 | Liletta |
| Coopersurgical, INC. | $73.49 | 2023 | Endosee |
| Exeltis, USA INC. | $58.92 | 2021-2024 | Slynd |
| Merck Sharp & Dohme LLC | $54.74 | 2024-2025 | Gardasil, Gardasil 9 |
| Shield Therapeutics INC | $50.63 | 2024 | |
| Sage Therapeutics, LLC | $46.31 | 2024-2025 | Zurzuvae |
| Becton, Dickinson and Company | $27.34 | 2024 | Bd Max System, Bd Max Instrument |
| Minerva Surgical, INC | $14.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.